Showing results (1-10 of 477) with videos related to
Sort By:
Pageof 48
Clinical Lymphoma, Myeloma & Leukemia|March 12, 2013
Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditionsElisabet E Manasanch, Sigurdur Y Kristinsson, Ola LandgrenEuropean Journal of Haematology|October 12, 2013
Smoldering multiple myeloma: present position and potential promisesNishant Tageja, Elisabet E Manasanch, Neha Korde, et al.Hematology. American Society of Hematology. Education Program|December 7, 2019
What to do with minimal residual disease testing in myelomaElisabet E ManasanchSeminars in Oncology|January 8, 2017
Recommend maintenance therapy with lenalidomide in multiple myelomaElisabet E ManasanchLeukemia & Lymphoma|November 23, 2013
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaElisabet E Manasanch, Neha Korde, Adriana Zingone, et al.Best Practice & Research. Clinical Haematology|March 7, 2020
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implicationsChutima Kunacheewa, Elisabet E ManasanchExpert Review of Hematology|September 22, 2021
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impactChutima Kunacheewa, Elisabet E ManasanchNature Reviews. Clinical Oncology|January 25, 2017
Proteasome inhibitors in cancer therapyElisabet E Manasanch, Robert Z OrlowskiOncotargets and Therapy|March 1, 2017
Carfilzomib boosted combination therapy for relapsed multiple myelomaRaphael E Steiner, Elisabet E ManasanchSeminars in Hematology|May 16, 2018
MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical ToolOla LandgrenPageof 48